News/ News/ R&D Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis Phil Taylor beta thalassaemia, gene editing, Haematology, Novartis, partnering, Precision BioSciences, sickle cell disease 0 Comment Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Share X Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis https://pharmaphorum.com/news/precision-bio-climbs-on-near-1-5bn-sickle-cell-pact-with-novartis/